Literature DB >> 32069515

Fibrinolysis and the Immune Response in Trauma.

Robert L Medcalf1, Charithani B Keragala1, Dominik F Draxler1,2.   

Abstract

It has long been known that the fibrinolytic system becomes activated following trauma. At first glance, this is not at all surprising and would appear to be in response to coagulation and the apparent need to remove blood clots and restore blood flow. However, in a bleeding patient, the opposite is what is actually needed. Therefore, one may ask why the fibrinolytic system gets activated in the first place or is there another purpose? Or is it that the waxing and waning of hemostasis in such severely injured patients creates a "moving target" such that the fibrinolytic system itself is constantly responding to changing circumstances? Depending on the injury modalities and the time point post injury, the fibrinolytic system could be either turned on or off. Various theories now abound that offer new insights into the turmoil and paradoxes associated with the fibrinolytic system in this unique setting and the use of antifibrinolytic agents. While this presents one conundrum, there is also another dimension to add to this discussion that has nothing to do with hemostasis per se but rather with the modulation of other critical processes that are also essential for optimal recovery following severe injury. Indeed, overwhelming data are now supporting an important role of the fibrinolytic system in the removal of necrotic tissue (mortolysis) and as a modulator of the innate immune response. Therefore, what is really going on when the fibrinolytic system decides to go into overdrive and generate plasmin, albeit even briefly after a traumatic event? Moreover, what other consequence may occur when antifibrinolytic agents are administered? This review will address this developing story and will outline a hypothesis that places the fibrinolytic system as a gateway to a myriad of processes that are not only linked to fibrin removal but are also broader players in the modulation of innate immunity. Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Entities:  

Year:  2020        PMID: 32069515     DOI: 10.1055/s-0040-1702170

Source DB:  PubMed          Journal:  Semin Thromb Hemost        ISSN: 0094-6176            Impact factor:   4.180


  5 in total

1.  Plasma levels of D-dimer and fibrin degradation product are unreliable for diagnosing periprosthetic joint infection in patients undergoing re-revision arthroplasty.

Authors:  Hong Xu; Jinwei Xie; Duan Wang; Qiang Huang; Zeyu Huang; Zongke Zhou
Journal:  J Orthop Surg Res       Date:  2021-10-19       Impact factor: 2.359

2.  Not all patients benefit from the postoperative antifibrinolytic treatment: clinical evidence against the universal use of tranexamic acid following total knee arthroplasty.

Authors:  Jiacheng Liu; Han Wang; Xiangdong Wu; Yiting Lei; Wei Huang
Journal:  J Orthop Surg Res       Date:  2022-01-29       Impact factor: 2.359

3.  Effects of tranexamic acid on coagulofibrinolytic markers during the early stage of severe trauma: A propensity score-matched analysis.

Authors:  Satoshi Gando; Atsushi Shiraishi; Takeshi Wada; Kazuma Yamakawa; Seitaro Fujishima; Daizoh Saitoh; Shigeki Kushimoto; Hiroshi Ogura; Toshikazu Abe; Toshihiko Mayumi; Junichi Sasaki; Joji Kotani; Naoshi Takeyama; Ryosuke Tsuruta; Kiyotsugu Takuma; Shin-Ichiro Shiraishi; Yasukazu Shiino; Taka-Aki Nakada; Kohji Okamoto; Yuichiro Sakamoto; Akiyoshi Hagiwara; Satoshi Fujimi; Yutaka Umemura; Yasuhiro Otomo
Journal:  Medicine (Baltimore)       Date:  2022-08-12       Impact factor: 1.817

Review 4.  Plasmin, Immunity, and Surgical Site Infection.

Authors:  Stuart Hastings; Paul S Myles; Robert L Medcalf
Journal:  J Clin Med       Date:  2021-05-12       Impact factor: 4.241

5.  Fibrinolysis and COVID-19: A plasmin paradox.

Authors:  Robert L Medcalf; Charithani B Keragala; Paul S Myles
Journal:  J Thromb Haemost       Date:  2020-07-15       Impact factor: 16.036

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.